GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenetic Biosciences Inc (NAS:XBIO) » Definitions » EV-to-EBIT

Xenetic Biosciences (Xenetic Biosciences) EV-to-EBIT : 0.43 (As of May. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Xenetic Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xenetic Biosciences's Enterprise Value is $-2.09 Mil. Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.87 Mil. Therefore, Xenetic Biosciences's EV-to-EBIT for today is 0.43.

The historical rank and industry rank for Xenetic Biosciences's EV-to-EBIT or its related term are showing as below:

XBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -1257.28   Med: -1.46   Max: 1.39
Current: 0.43

During the past 13 years, the highest EV-to-EBIT of Xenetic Biosciences was 1.39. The lowest was -1257.28. And the median was -1.46.

XBIO's EV-to-EBIT is ranked better than
81.32% of 423 companies
in the Biotechnology industry
Industry Median: 10.05 vs XBIO: 0.43

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Xenetic Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was $-2.01 Mil. Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-4.87 Mil. Xenetic Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 241.80%.


Xenetic Biosciences EV-to-EBIT Historical Data

The historical data trend for Xenetic Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenetic Biosciences EV-to-EBIT Chart

Xenetic Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 -1.35 0.16 1.31 0.81

Xenetic Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.26 0.47 0.81 0.41

Competitive Comparison of Xenetic Biosciences's EV-to-EBIT

For the Biotechnology subindustry, Xenetic Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenetic Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenetic Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xenetic Biosciences's EV-to-EBIT falls into.



Xenetic Biosciences EV-to-EBIT Calculation

Xenetic Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-2.091/-4.869
=0.43

Xenetic Biosciences's current Enterprise Value is $-2.09 Mil.
Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenetic Biosciences  (NAS:XBIO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Xenetic Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-4.869/-2.0136364
=241.80 %

Xenetic Biosciences's Enterprise Value for the quarter that ended in Mar. 2024 was $-2.01 Mil.
Xenetic Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xenetic Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Xenetic Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenetic Biosciences (Xenetic Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
945 Concord Street, Framingham, MA, USA, 01701
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
Executives
Grigory G. Borisenko director 40 SPEEN STREET, SUITE 102, FRAMINGHAM MA 01701
Alexey Andreevich Vinogradov director C/O XENETIC BIOSCIENCES, INC., 40 SPEEN STREET, FRAMINGHAM MA 01701
Adam Logal director OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
James Eric Callaway director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Dmitry Genkin director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
James F Parslow officer: Chief Financial Officer C/O XENETIC BIOSCIENCES, INC., 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Curtis Lockshin officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137
Benz Edward J. Jr director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Roger D. Kornberg director 345 WALSH ROAD, ATHERTON CA 94027
Darlene M Deptula-hicks director C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Jeffrey F Eisenberg director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Firdaus J. Dastoor director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Michael Scott Maguire director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Roman Knyazev director 99 HAYDEN AVENUE, SUITE 230, LEXINGTON MA 02421
Pharmsynthez Pjsc 10 percent owner 25 LITER KRASNOVO KURSANTA STREET, ST. PETERSBURG 1Z 197110

Xenetic Biosciences (Xenetic Biosciences) Headlines